Full Comparison Table

FeatureMK-677 (Ibutamoren)HGH (Somatropin)
FormOral capsule/liquidSubcutaneous injection
AdministrationOnce daily (oral)Daily SQ injection (or 5-on-2-off)
Cost/month~$50–150 (research compound)$800–$2,000+ (pharma US); cheaper overseas
IGF-1 Effect30–60% increase from baseline (dose-dependent)Larger, more controllable; depends on dose
MechanismGhrelin receptor agonist → stimulates pituitary GHDirect GH replacement
Pituitary SuppressionNone — preserves natural axisProgressive suppression over time
Appetite EffectIncreased (ghrelin mimicry)Minimal direct effect on appetite
Water RetentionCommon, especially early onDose-dependent; higher at 2–4 IU/day
Legal Status (US)Unscheduled research chemical (no Rx needed)Prescription required; Schedule III
Monitoring NeededIGF-1 at 12 weeks; fasting glucoseIGF-1 every 3–6 months; glucose; full panel
PCT RequiredNoNo (but axis recovery takes time off-drug)

Who Should Choose MK-677?

  • Peptide newcomers who want GH axis support without needles
  • Budget-conscious individuals (MK-677 is 10–20x cheaper than pharma HGH)
  • Users prioritizing sleep quality improvement as primary goal
  • Those who want IGF-1 support without pituitary suppression
  • Travelers or those with compliance concerns (no refrigeration needed)

Who Should Choose HGH?

  • Clinically diagnosed adult GH deficiency (low IGF-1 + stimulation test confirmed)
  • Older patients whose pituitary reserve has declined (secretagogues less effective)
  • Those seeking maximum, controllable IGF-1 elevation
  • Patients already on HGH therapy transitioning off peptide stacks
  • Physicians who need precise dose control for deficiency replacement

IGF-1 Response: What the Data Shows

Both MK-677 and HGH reliably raise IGF-1 — the downstream marker used to assess GH axis activity. The key differences are in the magnitude, predictability, and ceiling of the IGF-1 response.

  • MK-677 at 10mg: Typically raises IGF-1 by 20–30% from baseline. Sustained elevation due to once-daily dosing; not pulsatile. Well-documented in Phase 2 clinical trials.
  • MK-677 at 25mg: Raises IGF-1 by 40–60%. At this dose, some individuals approach or exceed the upper limit of the normal age-adjusted range, requiring monitoring.
  • HGH at 1 IU/day: Variable but typically produces a mid-to-upper normal IGF-1 response. More controllable via dose titration than MK-677.
  • HGH at 4 IU/day: Often produces supraphysiologic IGF-1 without careful monitoring. This dose range is associated with significantly higher side effect risk including carpal tunnel, insulin resistance, and joint pain.

Frequently Asked Questions

Is MK-677 as effective as HGH for raising IGF-1?

MK-677 raises IGF-1 by 30–60% depending on dose. HGH can produce a larger, more controllable rise — particularly at 2–4 IU/day. For borderline-low IGF-1 or longevity goals, MK-677 is often sufficient. For diagnosed GH deficiency, HGH is more potent and appropriate.

Does MK-677 suppress the pituitary like HGH does?

No. MK-677 stimulates the pituitary to release its own GH — the natural feedback loop remains intact. Exogenous HGH, by contrast, progressively suppresses pituitary GH output through negative feedback. No PCT is needed for MK-677.

What is the real cost difference between MK-677 and HGH?

MK-677 as a research compound costs approximately $50–150/month. Pharmaceutical HGH (Norditropin, Humatrope, etc.) costs $800–$2,000+ per month in the US without insurance. Compounded or overseas HGH is cheaper but carries quality and legal risks. MK-677 is dramatically more accessible.

Is MK-677 legal without a prescription?

In the US and most countries as of 2026, MK-677 is an unscheduled research chemical — no prescription is required. HGH is a Schedule III controlled substance in the US; a prescription is legally required to obtain it.

Track Your GH Protocol Free with Shotlee